丹麦制药巨头重大调整

药智网2025-07-30

图片来源：诺和诺德官网诺和诺德公告表示，业绩预期下调主要受核心产品司美格鲁肽销售额增长放缓影响：1.美国减肥药Wegovy增长放缓：受不安全非法GLP-1 compounded持续使用、市场扩张慢于预期及竞争加剧影响。一方面，诺和诺德市场调研显示，尽管FDA对非法compounded的宽限期已结束，但多家机构以“个性化定制”为幌子销售复合GLP-1药物。公司正通过诉讼等多项策略保护患者免受仿冒“司...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555178960?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-30 17:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2555178960","market":"us","top_or_hot":-1,"title":"丹麦制药巨头重大调整","media":"药智网","content":"<div>\n<p>图片来源：诺和诺德官网诺和诺德公告表示，业绩预期下调主要受核心产品司美格鲁肽销售额增长放缓影响：1.美国减肥药Wegovy增长放缓：受不安全非法GLP-1 compounded持续使用、市场扩张慢于预期及竞争加剧影响。一方面，诺和诺德市场调研显示，尽管FDA对非法compounded的宽限期已结束，但多家机构以“个性化定制”为幌子销售复合GLP-1药物。公司正通过诉讼等多项策略保护患者免受仿冒“司...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730174656a6c97cf8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>丹麦制药巨头重大调整</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n丹麦制药巨头重大调整\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-30 17:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730174656a6c97cf8&s=b><strong>药智网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>图片来源：诺和诺德官网诺和诺德公告表示，业绩预期下调主要受核心产品司美格鲁肽销售额增长放缓影响：1.美国减肥药Wegovy增长放缓：受不安全非法GLP-1 compounded持续使用、市场扩张慢于预期及竞争加剧影响。一方面，诺和诺德市场调研显示，尽管FDA对非法compounded的宽限期已结束，但多家机构以“个性化定制”为幌子销售复合GLP-1药物。公司正通过诉讼等多项策略保护患者免受仿冒“司...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730174656a6c97cf8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730174656a6c97cf8&s=b","article_id":"2555178960","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730174656a6c97cf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555178960","pubTimestamp":1753867988,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"公司正通过诉讼等多项策略保护患者免受仿冒“司美格鲁肽”药物危害，并呼吁联邦及州监管机构加强执法。不过，CVS全国模板处方集变更已于2025年7月1日生效，使Wegovy成为唯一纳入肥胖症覆盖的GLP-1药物，预计将产生积极影响。一方面受到礼来替尔泊肽等同类创新药的强势追击，另一方面受到非法仿制药的市场挤压，销售额增速并未如预期般高歌猛进。7月29日，诺和诺德宣布任命Maziar Mike Doustdar为总裁兼首席执行官，该任命自2025年8月7日起生效。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4532":"文艺复兴科技持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4599":"减肥药","NVO":"诺和诺德","BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"Danish pharmaceutical giant makes major shake-up","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":0.9},"content_text":"图片来源：诺和诺德官网诺和诺德公告表示，业绩预期下调主要受核心产品司美格鲁肽销售额增长放缓影响：1.美国减肥药Wegovy增长放缓：受不安全非法GLP-1 compounded持续使用、市场扩张慢于预期及竞争加剧影响。一方面，诺和诺德市场调研显示，尽管FDA对非法compounded的宽限期已结束，但多家机构以“个性化定制”为幌子销售复合GLP-1药物。公司正通过诉讼等多项策略保护患者免受仿冒“司美格鲁肽”药物危害，并呼吁联邦及州监管机构加强执法。另一方面，尽管2025年上半年推出新商业活动，但渗透率仍低于预期。不过，CVS全国模板处方集变更已于2025年7月1日生效，使Wegovy成为唯一纳入肥胖症覆盖的GLP-1药物，预计将产生积极影响。2.美国糖尿病药物Ozempic增长趋缓：市场竞争压力增大。3.国际业务（IO）市场Wegovy渗透率低于预期。司美格鲁肽是诺和诺德的王牌产品，其三个品牌合计销售额在2024年接近300亿美元，今年一季度销售额79亿美元，成功超过K药，成为新的“药王”。但是正如诺和诺德所言，司美格鲁肽无论是减肥版还是降糖版都面临激烈竞争。一方面受到礼来替尔泊肽等同类创新药的强势追击，另一方面受到非法仿制药的市场挤压，销售额增速并未如预期般高歌猛进。资料来源：根据诺和诺德财报整理在业绩和股价双重压力下，今年5月，诺和诺德执掌八载的CEO Lars Fruergaard Jørgensen宣布即将离任。7月29日，诺和诺德宣布任命Maziar Mike Doustdar为总裁兼首席执行官，该任命自2025年8月7日起生效。据悉，Maziar Mike Doustdar于2013年出任诺和诺德国际业务高级副总裁，管辖诺和诺德除美国外全部80家子公司。他在创造价值与推动增长方面成绩卓著。过去十年间，其领导的国际业务销售额增长逾一倍，2024年达到约1120亿丹麦克朗。诺和诺德在8月7日生效的组织架构调整还包括：研究与早期开发（Research&Early Development）和开发（Development）两大业务领域将合并为统一研发部门。现任开发执行副总裁Martin Holst Lange医学博士将出任首席科学官（CSO）。研究与早期开发执行副总裁兼CSO Marcus Schindler决定退休。现任欧洲与加拿大区（EUCAN）高级副总裁Emil Kongshøj Larsen将加入高管团队，接替Mike Doustdar出任国际业务执行副总裁。在新的组织架构下，诺和诺德能否重振雄风，引领糖尿病与肥胖治疗领域，全球资本市场正拭目以待。1.https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=9164072.https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916408声明：本内容仅用作医药行业信息传播，不代表药智网立场。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑| 小月石合作、投稿|马老师18323856316（同微信）阅读原文，是受欢迎的文章哦","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555178960","isCrawlerRequest":true}